SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 29.32+4.6%Oct 31 9:30 AM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John T. Harbaugh who wrote (185)8/15/1997 12:01:00 AM
From: JanyBlueEyes   of 5736
 
John, please state for us exactly what your specialty is in the field of medicine. What kind of a doctor are you? Do you have first hand experience with the testing of babies in hospitals? I am not trying to flame you.

Let me give you a scenario: A baby is born and a routine "Chem 23" is performed. It shows an elevated bilirubin level. All other levels are normal. Wouldn't a non-invasive machine like the Colormate tend to be used instead of drawing blood 3-4 times a day to monitor the baby's bilirubin?

I can tell you from personal experience (3 babies) that all 3 of my girls had elevated levels that had to be monitored by the nurses.

Here is some information from the Mt. Sinai Journal Of Medicine Oct '94. Remember this hospital did the clinical testing for Chromatics.
mssm.edu

.............To avoid some of the known problems with transcutaneous devices, we are in the midst of evaluating a computerized photosensor (Chromatics) that takes advantage of a wealth of information on skin tone available to s the cosmetics industry. Instead of registering the simple change in skin color caused by bilirubin, the Chromatics meter can measure minute alterations in any one of a vast array of human skin types. This patient-specific analysis takes account of race and skin perfusion and, in effect, allows the computer to "see bilirubin" below the surface. Preliminary results (45 ' ) suggest a degree of accuracy and linearity not available in other f devices. Surprisingly, phototherapy does not seem to interfere with the measurement, even though infants, while being treated, appear less jaundiced to the eye, This suggests that the depth of measurement by this new device exceeds that which influences the visual assessment of skin color.

The value of the Chromatics meter, or any other screening tool, ultimately rests on the clinician's need to measure bilirubin in the newborn. The trends toward extremely early discharge after delivery, cost containment, and decreases in medical interventions should increase our requirements for simple and safe methods of determining which infants have more than just "physiologic" jaundice. If we couple this with a rational use of phototherapy, and newer treatments to eliminate hyperbilirubinemia, the incidence of significant hyperbilirubinemia may be reduced.........
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext